Zanamivir-resistant influenza viruses with a novel neuraminidase mutation - sprookjes - yvandenbroek - TriplyDB

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

http://www.wikidata.org/entity/Q30379353

about

Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase.Reverse Genetics Approaches for the Development of Influenza Vaccines Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013 Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study Comparison of mutation patterns in full-genome A/H3N2 influenza sequences obtained directly from clinical samples and the same samples after a single MDCK passage The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model Coadministration of Hedera helix L. Extract Enabled Mice to Overcome Insufficient Protection against Influenza A/PR/8 Virus Infection under Suboptimal Treatment with Oseltamivir High-Efficiency Capture of Drug Resistant-Influenza Virus by Live Imaging of Sialidase Activity Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages Drug resistance in influenza A virus: the epidemiology and management.The pharmacological management of severe influenza infection - 'existing and emerging therapies'.Molecular evolution of the hemagglutinin and neuraminidase genes of pandemic (H1N1) 2009 influenza viruses in Sendai, Japan, during 2009-2011.Akt inhibitor MK2206 prevents influenza pH1N1 virus infection in vitro.Anti-high mobility group box-1 monoclonal antibody treatment provides protection against influenza A virus (H1N1)-induced pneumonia in mice.Seasonal, avian, and novel H1N1 influenza: prevention and treatment modalities.Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.The early diversification of influenza A/H1N1pdm.Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase Novel (pandemic) influenza A H1N1 in healthcare facilities: implications for prevention and control.Targeting pandemic influenza: a primer on influenza antivirals and drug resistance.Aerosol and nasal delivery of vaccines and antiviral drugs against seasonal and pandemic influenza.Networks of Host Factors that Interact with NS1 Protein of Influenza A Virus Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.Influenza mixes its pitches: Lessons learned to date from the influenza A (H1N1) pandemic Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system Oseltamivir-resistant pandemic (H1N1) 2009 virus, Mexico.Neuraminidase inhibitor sensitivity and receptor-binding specificity of Cambodian clade 1 highly pathogenic H5N1 influenza virus Strategies for the use of oseltamivir and zanamivir during pandemic outbreaks.Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States.Multidrug-resistant pandemic (H1N1) 2009 infection in immunocompetent child Influenza: clinical symptoms, diagnostics and therapy Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

P2860

Q26822988-90C8C855-8072-4C1F-B8CA-7611DD7F119A Q27013442-C368EE41-3459-4E10-A8B7-8DBB72B6F8EF Q27314689-4003027D-1C6C-4358-84C3-50DFAF176E54 Q27665921-A40A2FEA-F7C5-479B-9544-92983D2EEBBD Q28076140-737A3E97-1DB0-454D-9AF1-CC76DC8203D3 Q28386096-67E719DF-1C65-4C49-A150-25A99FABB193 Q28478637-1046FF53-F106-4D48-AD6B-DC6C8331C0A2 Q28483402-2009C1C6-4392-4E53-8FD3-C4A599260902 Q28483631-EC79434D-13D5-4EBD-BA79-DE06CD85CAB4 Q28534776-D57AC5E4-BE52-4464-99FF-5923C8E9957D Q28547982-28B77DC1-ED0E-4EE3-ADD6-B608DD1B95C3 Q28548533-4C98C960-7076-4AC8-B235-B2013640DEC1 Q28552500-4AF5C8E8-8F0D-43AB-AE23-D2BEB5967214 Q30202859-3C0C6D57-25AB-48FF-BF6C-4464BCA79603 Q30227284-2B2FD90E-0389-445D-BAE6-6BB00CC9DB84 Q30234600-4E8211C8-4736-4263-8FA5-509E3D55DF64 Q30243907-6D3CC109-69CA-4B43-B58C-5E91171AB823 Q30354016-245BF243-F3C5-41F9-BBF5-410BEBB8E60C Q30361598-43B577F5-1646-4C00-BD8D-AD62A55ECB0D Q30375577-896313CD-161D-414B-922D-E16BA00E9354 Q30382632-2BBD2E51-1378-4311-BD10-A105FDF44A8C Q30383771-251F0863-7B8A-4694-BFF0-C1169D59C6EC Q30383816-1A8D3DEC-1867-4264-9823-0C08D8355836 Q30385853-3189B06F-EE42-4770-AE6F-413004FD5768 Q30387212-5C5B0DFC-8936-43CA-8688-7E3778D6ED46 Q30387832-C35E98EA-7AC0-41DE-81CA-600F1420B080 Q30388296-A29078D8-9C6F-4633-BFDF-B5D87D4223BA Q30388331-B4FA76A8-A29A-4C42-AA7C-924F44C4CFAE Q30390818-4C0ECC44-2266-4E80-868E-28A359414FF2 Q30393202-140CC1B2-CFFF-459B-B68C-A442C2B8DF20 Q30397253-407F72E8-7E5E-4827-9CDE-69E7E32DC008 Q30398804-AD1BF5DD-5B0E-49BA-A112-8D1C27F0DE3C Q30398935-427DF3C7-6406-4FC4-874F-93ABC0E7F8D1 Q30399321-50C4B1BD-D005-4560-AC7A-79F91AECA903 Q30400058-56D3D56E-8016-4E5F-9209-FFDC53D901D9 Q30400232-B3935AF7-7BC2-4DF9-907C-DDB5CAB13CF5 Q30400342-6341AABE-B038-45E3-8368-7B90EA7C126C Q30405407-4EBB6BE6-628D-450C-B294-5D7A36E95A63 Q30405546-250CCD13-F767-4252-87A9-D41067812142 Q30408105-AF5CFA05-72F4-42F4-ADB5-129715031F55

P2860

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

http://www.wikidata.org/entity/Q30379353

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@ast

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@en

type

label

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@ast

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@en

prefLabel

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@ast

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@en

P1433

Q30379353-5D32A6D1-9174-4952-87B2-2A1FDD83D261

P1476

Q30379353-A4C5A9BF-EEA7-4586-8416-730D5B8A60BB

P2093

Q30379353-085D8C13-8971-4F8F-B2FA-6978BE5295CF

Q30379353-DDEC18BC-0356-4B90-9587-CDCF4102426A

P2860

Q30379353-0D5CE25D-F391-433A-9CA7-5603AD189AAA

Q30379353-11267D81-63EE-4F82-8BAC-436B66F41B70

Q30379353-1ADD889D-00C9-4D8D-9393-6C7F9BD86075

Q30379353-1C6C9345-90C3-42E3-971D-8F25053CD0E0

Q30379353-30CFA299-F9C2-4FAA-A96E-C5DB6A108BB0

Q30379353-31FFC5A9-9BB2-4CB9-93AD-880F2504CAEF

Q30379353-4B986959-9917-409A-9F54-C958871B1BFC

Q30379353-6194E1EF-67E5-426E-982A-0061F0E7700D

Q30379353-6ED51153-3232-4E2E-9A42-A55096BF2254

Q30379353-788C57A7-0612-40A5-98B1-6719E7147572

P304

Q30379353-60871B46-BDEB-4900-8E9D-50C9749CBDBB

P31

Q30379353-2C6C40DB-5666-4F38-B2D0-8B84C61D0DAE

P356

Q30379353-8536797D-CDE4-419A-AD8C-CB1823AB9CCF

P433

Q30379353-2B1DE94A-EF8E-4D7A-92DD-70C8D9B5F357

P478

Q30379353-A5B7A323-3941-4DC2-9117-E82A9CBDCE41

P50

Q30379353-7C7AC99E-2FCB-4B80-A8CF-5B3B86E7ED08

Q30379353-7F9A0676-FB15-400A-B9F5-72D0BA52E22B

Q30379353-F4880D1D-1B11-430F-9784-CE14326E8777

P577

Q30379353-1D0CE57A-D6FB-483A-A2F5-BDC88D50DD94

P5875

Q30379353-9B92C37B-1A37-4041-ACC2-10DB3495D8E1

P698

Q30379353-A65E0D57-9EE5-45BF-8795-2DA254DCF99B

P932

Q30379353-D732A21E-FF6B-47FA-B35A-A678D1EB4C3F

P356

P1433

Journal of Virology

P1476

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation

@en

P2093

Jessica K Holien

http://www.w3.org/2001/XMLSchema#string

Michael Parker

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.

Oseltamivir resistance during treatment of influenza A (H5N1) infection

Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay.

Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic.

Avian flu: isolation of drug-resistant H5N1 virus.

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

P304

10366-10373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01200-09

http://www.w3.org/2001/XMLSchema#string

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

83

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-07-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26703789

http://www.w3.org/2001/XMLSchema#string

P698

19641000

http://www.w3.org/2001/XMLSchema#string

P932

2753113

http://www.w3.org/2001/XMLSchema#string